Sign In
Buy ALEC
$1.51
-0.110 (-6.79%)
At Close: Jul 31, 2026
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
11:23pm, Tuesday, 27'th Feb 2024
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Tuesday, 27'th Feb 2024
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
04:05pm, Tuesday, 20'th Feb 2024
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
11:06am, Tuesday, 20'th Feb 2024
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
07:51am, Thursday, 08'th Feb 2024
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 28
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
07:00am, Wednesday, 07'th Feb 2024
-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Thursday, 25'th Jan 2024
Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
07:32am, Tuesday, 23'rd Jan 2024
Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some
Alector Announces Closing of Public Offering
09:20am, Friday, 19'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its unde
Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation
05:32pm, Wednesday, 17'th Jan 2024
Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using
Alector Announces Pricing of Public Offering of Common Stock
08:54am, Wednesday, 17'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an under
Alector Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 16'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offe
Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet
11:17am, Tuesday, 05'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the posit
These biotechs targeting multiple neurodegenerative diseases
08:15am, Friday, 01'st Dec 2023
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive
